About Cipla:
Mumbai is home to Cipla Limited, a multinational pharmaceutical business from India. Cipla mainly creates drugs to address disorders like depression, diabetes, rheumatoid arthritis, and cardiovascular disease.
Mumbai serves as the corporate headquarters of the international Indian pharmaceutical business Cipla Limited, often known as Cipla. Cipla mainly creates drugs to address disorders like depression, diabetes, rheumatoid arthritis, and cardiovascular disease.
Cipla offers its goods in 86 countries and operates 47 manufacturing facilities worldwide. It is India’s third-biggest pharmaceutical manufacturer.
Khwaja Abdul Hamied established Cipla as the Chemical, Industrial & Pharmaceutical Laboratories in Mumbai in 1935. The company’s name was changed to “Cipla” in July 1984.
Cipla supplies pharmaceutical and personal care companies with active pharmaceutical components, such as the antidepressants escitalopram oxalate, lamivudine, and fluticasone propionate. Cipla is the biggest producer of antiretroviral medications worldwide.
Cipla Share Price:
Tuesday saw a nearly 8% increase in Cipla shares during mid-session trading, one day after the business revealed a 32.25% increase in third-quarter profit to ₹1,068.41 crore.
On the BSE, the company’s shares increased 7.73 percent to trade at ₹1,414 a share. Cipla’s share price increased 7.47 percent to 1,414.60 per piece on the NSE.
The 30-share BSE Sensex fell 708.90 points, or 0.99 percent, to trade at 70,714.75, during the mid-day trading session on January 23. Meanwhile, the NSE Nifty down 1.05 percent to trade at 21,344.40 points.
Cipla Ltd, a pharmaceutical company, announced a 32.25% increase in consolidated profit to ₹1,068.41 crore for the third quarter that ended in December 2023 in a regulatory filing on January 22.
In the same quarter last year, the company reported a consolidated profit of ₹807.83 crore. The company reported that its consolidated revenue from operations for the reviewed quarter was ₹6,603.81 crore, an increase of 13.66%.
It was ₹5,810.09 crore during the same time last year.
Its overall expenses for the December quarter of the previous fiscal year were ₹5,119.81 crore, 8.78 per cent more than those for the October–December quarter of the previous year, ₹4,706.47 crore.
Cipla’s total revenue increased by 14.58% to ₹6.788.44 crore during the third quarter. Its income for the quarter came from new ventures at ₹280.51 crore and from pharmaceuticals at ₹6,365.06 crore.
